“Intellectual Property” means all intellectual property and industrial property rights and all rights, interests and protections that are associated with any of the foregoing, however arising, pursuant to the Laws of any jurisdiction throughout the world, whether registered or unregistered, including any and all: (a) trademarks, service marks, trade names, brand names, logos, trade dress, design rights and other similar designations of source, sponsorship, association or origin, together with the goodwill connected with the use of and symbolized by, and all registrations, applications and renewals for, any of the foregoing; (b) internet domain names, whether or not trademarks, registered in any top-level domain by any authorized private registrar or Governmental Authority, web addresses and URLs; (c) works of authorship, expressions, designs and design registrations, whether or not copyrightable, including copyrights, author, performer, moral and neighboring rights, and all registrations, applications for registration and renewals of such copyrights; (d) inventions, discoveries, trade secrets, databases, data collections and all rights therein; (e) patents (including all reissues, divisionals, provisionals, continuations and continuations-in-part, re-examinations, renewals, substitutions and extensions thereof), patent applications, and other patent rights and any other Governmental Authority-issued indicia of invention ownership (including inventor’s certificates, petty patents, and patent utility models); and (f) software and firmware, including source code, object code, application programming interfaces, computerized databases; and (g) semiconductor masks, integrated circuit topographies, and mask works.
“Intellectual Property Indemnification Cap” has the meaning set forth in Section 9.04(a)(i).
“Janssen R&D” means Janssen Research & Development, LLC.
“Knowledge”, and any other similar qualification as to awareness, means, when used with respect to the Company, the actual knowledge of any director or officer of the Company, after reasonable inquiry.
“Laboratory Lease” means the License Agreement dated April 10, 2017, between Janssen R&D and the Company, as supplemented by Addendum 1 between the Company, Janssen R&D, and Janssen Biotech Inc., dated effective June 6, 2017, and as amended by the 1st Amendment to License Agreement dated February 27, 2018, and the Second Amendment to License Agreement dated November 13, 2018, in each case between the Company and Janssen R&D.
“Law” means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement or rule of law of any Governmental Authority.
“Letter of Transmittal” has the meaning set forth in Section 2.11(c).
“Liabilities” has the meaning set forth in Section 4.07.
“Licensed Intellectual Property” means all Intellectual Property, other than Owned Intellectual Property, that are either used in the Company’s business or licensed to the Company.
“Losses” mean losses, damages, liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys’ fees (on a solicitor or attorney-and-client basis), the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers; provided, however, that “Losses” shall not include punitive damages, except to the extent actually awarded to a Governmental Authority or other third party, or any reduction in any net operating loss, capital loss, Tax credit carryover or other Tax asset.
“Majority Holders” has the meaning set forth in Section 11.01(c).
“Material Adverse Effect” means any event, occurrence, fact, condition or change that is, or could reasonably be expected to become, individually or in the aggregate, materially adverse to (a) the business, results of operations, condition (financial or otherwise) or assets of the Company, or (b) the ability of the Company to consummate the transactions contemplated hereby on a timely basis; provided, however, that “Material Adverse Effect” shall not include any event, occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions; (ii) conditions generally affecting the industries in which the Company operates; (iii) any changes in financial or securities markets in general; (iv) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation or worsening thereof; (v) any action required or permitted by this Agreement, except pursuant to Section 4.03 and Section 6.09; (vi) any changes in applicable Laws or accounting rules, including GAAP; or (vii) the public announcement, pendency or completion of the transactions contemplated by this Agreement; provided further, however, that any event, occurrence, fact, condition or change referred to in clauses (i) through (iv) immediately above shall be taken into account in determining whether a Material Adverse Effect has occurred or could reasonably be expected to occur to the extent that such event, occurrence, fact, condition or change has a disproportionate effect on the Company compared to other participants in the industries in which the Company conducts its businesses.
-12-